Mike Trower has greater than 20 years drug discovery and development experience in the pharmaceutical industry.
He is a joint founder of NeRRe Therapeutics Ltd, and currently holds the positions of CSO & COO in the company. Mike was deeply involved in the acquisition of the Company’s neurokinin antagonist portfolio from GSK; where he was previously VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD).
In this position he had responsibility for defining & implementing the CEDD externalisation strategy and advancing a portfolio of preclinical and clinical pipeline assets. He has expert knowledge of the neurosciences, and neuronal hypersensitivity disorders relating to neurokinin receptor system biology as well as the transferred assets. He is also a member of The London Business School Alumni.